Lineage Cell Therapeutics (LCTX) Equity Ratio (2010 - 2026)

Lineage Cell Therapeutics has reported Equity Ratio for 17 years, with the latest figure at 0.49 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 29.22% year-over-year to 0.49; the trailing twelve-month figure through Mar 2026 stood at 0.49 (down 29.22% YoY), and the FY2025 full-year result was 0.39, down 43.4% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.49, up from 0.39 in the prior quarter.
• The five-year high for Equity Ratio was 0.69 in Q1 2025, with the low at 0.25 in Q3 2025.
• Historically, Equity Ratio has averaged 0.58 across 5 years, with a median of 0.61 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio grew 11.7% — and 2025, when it tumbled 63.35%.
• Lineage Cell Therapeutics' Equity Ratio stood at 0.58 in 2022, then climbed by 5.55% to 0.61 in 2023, then gained by 10.79% to 0.68 in 2024, then plunged by 43.4% to 0.39 in 2025, then increased by 27.75% to 0.49 in 2026.
• The last three Equity Ratio figures came in at 0.49 (Q1 2026), 0.39 (Q4 2025), and 0.25 (Q3 2025), per Business Quant data.